Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Artificial Urinary Sphincter Clinical Outcomes (AUSCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04088331
Recruitment Status : Recruiting
First Posted : September 12, 2019
Last Update Posted : June 3, 2022
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
To evaluate the AMS 800 Artificial Urinary Sphincter (AUS) in men with primary stress urinary incontinence as measured by pad weight tests.

Condition or disease Intervention/treatment
Stress Urinary Incontinence Device: AMS 800 Artificial Urinary Sphincter

Layout table for study information
Study Type : Observational
Estimated Enrollment : 175 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Artificial Urinary Sphincter Clinical Outcomes
Actual Study Start Date : October 14, 2019
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
AMS 800 Artificial Urinary Sphincter Recipients
Adult males with moderate to severe primary stress urinary incontinence (as assessed by a baseline pad weight test) due to ISD who meet the indications for surgical correction of urinary incontinence.
Device: AMS 800 Artificial Urinary Sphincter
The AMS 800 Artificial Urinary Sphincter (AUS) is an implantable, fluid filled, solid silicone elastomer device used to treat stress urinary incontinence due to reduced urethral/bladder outlet resistance (intrinsic sphincter deficiency). It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by opening and closing the urethra under the control of the patient.




Primary Outcome Measures :
  1. Number of subjects with reduction in 24 hour pad weight test at 12 months [ Time Frame: 12 months ]
    Number of subjects achieving 50% reduction or greater in baseline urinary incontinence as measured by 24-hour pad weight test at 12 months post device activation


Secondary Outcome Measures :
  1. Incidence of safety parameters [ Time Frame: 3 months, 6 months and 12 months ]
    Incidence of safety parameters at 3 months, 6 months, and 12 months. Safety parameters include device and/or procedure related adverse events, revision rates, and serious adverse events

  2. Number of subjects achieving ≥ 50% reduction in 24 hour pad weight test at 6 months [ Time Frame: Device Activation and 6 months ]
    Number of subjects achieving ≥ 50% reduction in urinary incontinence as measured by 24-hour pad weight test at device activation and 6 months post device activation compared to baseline

  3. Number of subjects achieving ≥ 75% reduction in 24 hour pad weight test at 6 and 12 months [ Time Frame: Device Activation, 6 months, and 12 months ]
    ≥ 75% reduction in urinary incontinence as measured by 24-hour pad weight test at device activation, 6 months, and 12 months post device activation compared to baseline

  4. Number of pads per day [ Time Frame: 3 months, 6 months, and 12 months ]
    Reduction in # of pads per day at 3 months, 6 months and 12 months post-device activation compared to baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
This study will enroll adult males with moderate to severe primary stress urinary incontinence (as assessed by a baseline pad weight test) due to ISD who meet the indications for surgical correction of urinary incontinence.
Criteria

Inclusion Criteria:

  1. Male
  2. ≥ 18 years of age
  3. Has undergone either a radical prostatectomy, transurethral resection of the prostate or other invasive prostate surgery
  4. Demonstrates primary stress urinary incontinence
  5. Positive screening 24-hour pad weight test (≥100 grams)
  6. Experiences at least 3 incontinence episodes per day during baseline diary or presents with continuous incontinence
  7. Negative urine culture
  8. Willing and able to undergo surgical implantation of the AUS device
  9. Willing and able to comply with the follow-up requirements
  10. Willing and able to forego any other surgical urinary incontinence treatments while participating in the study
  11. Willing and able to sign the informed consent

Exclusion Criteria:

  1. Previously had or currently has a device implanted (AUS/Sling, or otherwise) for treatment of SUI or urge incontinence
  2. Primary urgency incontinence
  3. Postvoid residual volume greater that 150 ml or a history of difficulty emptying the bladder
  4. Recurrent vesicourethral anastomotic stricture or urethral stricture disease within the past 6 months
  5. Known urogenital malignancy other than previously treated prostate cancer
  6. Recurrent prostate cancer that is expected to require intervention during the study follow-up period
  7. History of recurrent bladder stones within the past 12 months prior to signing the informed consent
  8. Neurogenic bladder
  9. Need for intermittent catheterization
  10. Known history of bleeding diathesis or coagulopathy
  11. Immunosuppressed or on medical therapy which would impact the immune system
  12. Uncontrolled diabetes, defined as (HbA1c>10)
  13. Has a genitourinary mechanical prosthesis that was implanted within 3 months from the date of consent
  14. Had a post-implantation infection associated with the device after genitourinary mechanical prosthesis was implanted
  15. Undergone bulking procedure within 6 months of the baseline assessment
  16. Poor candidate for surgical procedures and/or anesthesia due to physical or mental conditions
  17. Urinary incontinence due to or complicated by an irreversibly obstructed lower urinary tract
  18. Irresolvable detrusor hyperreflexia or bladder instability
  19. Currently enrolled or plans to enroll in another device or drug clinical trial
  20. Currently using an indwelling catheter or condom catheter for treatment of incontinence and is not willing to discontinue use at least 4 weeks prior to baseline assessment
  21. Known allergy or sensitivity to rifampin or to minocycline HCl or other tetracyclines (only applicable when implanting with InhibiZone version of this device)
  22. Systemic lupus erythematosus because minocycline HCl has been reported to aggravate this condition (only applicable when implanting with InhibiZone version of this device)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04088331


Contacts
Layout table for location contacts
Contact: Amara R Balhorn 651-202-1075 amara.balhorn@bsci.com

Locations
Show Show 18 study locations
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Layout table for investigator information
Principal Investigator: Melissa Kaufman, MD Vanderbilt Urology
Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT04088331    
Other Study ID Numbers: U0669
First Posted: September 12, 2019    Key Record Dates
Last Update Posted: June 3, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Incontinence
Urinary Incontinence, Stress
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations